Table 2.
Incident type specific median clearance time in months and risk of clearance by biomarkers of iron status.
|
|
|||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Any HPVa | Oncogenic HPV | Non-oncogenic HPV | HPV 16 | ||||||||||||
| n | Median (95% CI)b | Adjusted HR (95% CI)c | n | Median (95% CI) | Adjusted HR (95% CI) | n | Median (95% CI) | Adjusted HR (95% CI) | n | Median (95% CI) | Adjusted HR (95% CI) | ||||
|
|
|||||||||||||||
| Ferritind | |||||||||||||||
| Continuous | 453 | - | 0.94 (0.82, 1.06) | 226 | - | 0.89 (0.73, 1.10) | 227 | - | 0.96 (0.80, 1.14) | 57 | - | 0.60 (0.26, 1.41) | |||
| Dichotomize | |||||||||||||||
| <26.6 | 228 | 6.67 (6.01, 8.54) | Ref | 116 | 8.05 (6.08, 11.73) | Ref | 112 | 6.01 (5.88, 8.05) | Ref | 28 | 6.90 (5.95, 12.01) | Ref | |||
| ≥ 26.6 | 233 | 7.89 (6.01, 9.89) | 0.88 (0.72, 1.07) | 116 | 9.79 (6.28, 11.99) | 0.73 (0.55, 0.96) | 117 | 6.01 (5.68, 8.05) | 0.99 (0.76, 1.29) | 29 | 9.63 (6.01, 12.19) | 0.29 (0.11, 0.73) | |||
| sTfRd | |||||||||||||||
| Continuous | 453 | - | 1.17 (0.94, 1.45) | 226 | - | 1.14 (0.86, 1.51) | 227 | - | 1.14 (0.81, 1.60) | 57 | - | 0.45 (0.12, 1.71) | |||
| Dichotomize | |||||||||||||||
| < 1.97 | 232 | 6.54 (6.01, 8.54) | Ref | 117 | 7.95 (6.08, 11.73) | Ref | 115 | 6.01 (5.85, 8.05) | Ref | 33 | 7.95 (6.01, 12.52) | Ref | |||
| ≥ 1.97 | 229 | 7.95 (6.01, 11.01) | 0.94 (0.77, 1.16) | 115 | 10.81 (6.54, 11.96) | 0.80 (0.58, 1.10) | 114 | 6.01 (5.62, 9.03) | 1.00 (0.75, 1.33) | 24 | 6.70 (5.91, 11.99) | 0.54 (0.19, 1.52) | |||
| sTfR-F Indexd | |||||||||||||||
| Continuous | 453 | - | 1.12 (0.92, 1.36) | 226 | - | 1.07 (0.79, 1.44) | 227 | - | 1.14 (0.86, 1.51) | 57 | - | 0.56 (0.22, 1.48) | |||
| Dichotomize | |||||||||||||||
| <1.08 | 229 | 7.36 (6.01, 9.79) | Ref | 117 | 8.05 (6.08, 11.70) | Ref | 112 | 6.05 (5.85, 9.63) | Ref | 32 | 7.06 (5.95, 12.19) | Ref | |||
| ≥ 1.08 | 232 | 6.77 (6.01, 10.81) | 1.01 (0.82, 1.25) | 115 | 11.01 (6.44, 11.96) | 0.83 (0.60, 1.16) | 117 | 6.01 (5.68, 7.92) | 1.14 (0.86, 1.52) | 25 | 6.77 (6.01, 12.02) | 0.65 (0.33, 1.29) | |||
a
Infections, not women, were used as the unit of analyses for each outcome.
b
Log-Rank test for differences in median time to clearance were not significant for all comparisons.
c
All Cox models were adjusted for age, condom use, education, monthly income, menarche, lifetime number of sexual partners, oral contraceptive use, race, and smoking status.
d
Continuous measures of Iron Status were log transformed.
sTfR=Soluble transferrin receptor, CI=Confidence Interval, Ref=Reference group